Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Iodine I-123 Clear all
Recruiting Not applicable Interventional

Personalized Treatment in Thyroid Disorders

NCT03517579
View directory record Official record
Conditions
Thyroid Cancer, Graves Disease
Interventions
Cervical Collar Therapy Indicator (COTI)
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease

NCT00126425
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
123I-mIBG (meta-iodobenzylguanidine)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms

NCT00382967
View directory record Official record
Conditions
Parkinsonian Syndromes
Interventions
DaTSCAN SPECT imaging
Procedure
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 1, 2026, 10:24 PM EDT
Terminated Phase 1 Interventional

Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging

NCT01522378
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
123 iodine metaiodobenzylguanidine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

NCT00712829
View directory record Official record
Conditions
Prostate Cancer
Interventions
123-I-MIP-1072, 123-I-MIP-1095
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 1, 2026, 10:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Parkinson's Disease Biomarker Program

NCT01767818
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Years and older
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 1, 2026, 10:24 PM EDT
Terminated Phase 1 Interventional

Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy

NCT00788307
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ad5-CMV-NIS, Liothyronine Sodium, Reverse Transcriptase Polymerase Chain Reaction, laboratory biomarker analysis, Iodine I 131, Iodine I 123
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 1, 2026, 10:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients

NCT00001320
View directory record Official record
Conditions
Healthy, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 1, 2026, 10:24 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00870519
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
I-123-MNI-168, 123-I MNI-168
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 1, 2026, 10:24 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

NCT04385277
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, FDG-Positron Emission Tomography, Iobenguane I-123, Irinotecan, Isotretinoin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sargramostim, Temozolomide
Procedure · Biological · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
70
States / cities
Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 1, 2026, 10:24 PM EDT
Withdrawn Not applicable Interventional

The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG

NCT03227393
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Yoga training
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 1, 2026, 10:24 PM EDT
Enrolling by invitation Phase 4 Interventional

DaTSCAN Imaging in Aging and Neurodegenerative Disease

NCT01453127
View directory record Official record
Conditions
Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
Interventions
I-123 Ioflupane solution injection prior to SPECT scan (DaTscan), Single photon emission computed tomography (SPECT) scan
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 1, 2026, 10:24 PM EDT
Completed No phase listed Observational

Idiopathic Parkinson's Progression and Dopamine Transporter SPECT

NCT03531086
View directory record Official record
Conditions
Parkinson Disease
Interventions
Ioflupane I 123
Drug
Lead sponsor
Julie Gurwell
Other
Eligibility
40 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease

NCT00126438
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
123I-mIBG (meta-iodobenzylguanidine)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Sep 1, 2026, 10:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease

NCT00058721
View directory record Official record
Conditions
Parkinson Disease
Interventions
I-123-5-IA85380
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)

NCT03557333
View directory record Official record
Conditions
Migraine Headache
Interventions
INP104
Combination Product
Lead sponsor
Impel Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 1, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

NCT06440850
View directory record Official record
Conditions
Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions
Biospecimen Collection, Cobimetinib, Computed Tomography, Diagnostic Imaging, I-131 Uptake Test, Iodine I-131, Magnetic Resonance Imaging, Positron Emission Tomography, Recombinant Thyrotropin Alfa, Ultrasound Imaging, Vemurafenib
Procedure · Drug · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.

NCT01859767
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
[123I]MNI-672 SPECT
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
20 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 1, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

NCT06961084
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Iodine-124, Positron Emission Tomography (PET)/Computerized tomography (CT)
Drug · Procedure
Lead sponsor
Thomas Hope
Other
Eligibility
13 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 1, 2026, 10:24 PM EDT
Completed No phase listed Observational

Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death

NCT01919983
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Dilated Cardiomyopathy, Inflammation, Sudden Cardiac Death
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 1 Interventional

Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer

NCT00647153
View directory record Official record
Conditions
Colorectal Cancer
Interventions
pharmacological study, single photon emission computed tomography, iodine I 123 anti-CEA recombinant diabody T84.66
Other · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 1, 2026, 10:24 PM EDT
Completed No phase listed Observational Results available

Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event

NCT00785044
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
I-123 mIBG
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 1, 2026, 10:24 PM EDT
Terminated No phase listed Observational

Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery

NCT05591092
View directory record Official record
Conditions
Thyroid Gland Follicular Carcinoma
Interventions
Computed Tomography, Iodine I-123, Planar Imaging, Single Photon Emission Computed Tomography
Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Not applicable Interventional Results available

Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG

NCT01432626
View directory record Official record
Conditions
Stress Induced Cardiomyopathy
Interventions
I-123 radiolabeled metaiodobenzylguanidine cardiac imaging
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 1, 2026, 10:24 PM EDT